Search results for " Vaccines"

showing 10 items of 472 documents

July 2003: 62-year-old female with progressive muscular weakness

2004

The July 2003 Case of the Month (COM). A 62-year-old female patient experienced progressive muscular weakness over the last ten years, involving shoulder and pelvic girdle muscles, paraspinal and facial muscles. A biopsy was taken from the left deltoid muscle where hepatitis vaccination had taken place 4 weeks previously. The specimen revealed macrophagic myofasciitis due to the injection of aluminium-bound vaccines. The finding can be reproduced experimentally by injecting vaccines in rats. The pathomechanism is supposed to involve immune stimulation due to long term persistence of the adjuvant. Macrophagic myofasciitis has been suggested to occasionally cause myopathy but is supposed to b…

Viral Hepatitis Vaccinesmedicine.medical_specialtyAluminum HydroxideMass SpectrometryCases of the Month: July to September 2003Pathology and Forensic MedicineDiagnosis DifferentialBiopsymedicineHumansMuscle SkeletalMyopathyInclusion BodiesHepatitisMuscle WeaknessPelvic girdlemedicine.diagnostic_testbusiness.industryMacrophagesGeneral NeuroscienceMacrophagic myofasciitisMiddle Agedmedicine.diseaseMuscular Dystrophy FacioscapulohumeralSurgeryVaccinationMicroscopy ElectronFacial musclesmedicine.anatomical_structureFemaleNeurology (clinical)medicine.symptombusinessProgressive muscular weaknessBrain Pathology
researchProduct

Immunomodulatory effects of dietary β-1,3-glucan from Euglena gracilis in rainbow trout (Oncorhynchus mykiss) immersion vaccinated against Yersinia r…

2012

Abstract Potential immunostimulatory effects of orally administered β-glucan were investigated in combination with immersion vaccination against enteric redmouth disease caused by Yersinia ruckeri in rainbow trout (Oncorhynchus mykiss). A linear, unbranched and pure (purity ≥98%) β-1,3-glucan (syn. paramylon) from the alga Euglena gracilis was applied at an inclusion level of 1% β-glucan in feed administered at a rate of 1% biomass day−1 for 84 consecutive days. Fish were vaccinated after two weeks of experimental feeding and bath challenged with live Y. ruckeri six weeks post-vaccination. Blood and head kidney were sampled at day 0, 13 (1 day pre-vaccination), 15, 55, 59 (day 3 post-challe…

Yersinia ruckeribeta-GlucansYersinia InfectionsAquatic ScienceMicrobiologyAndrologyFish Diseaseschemistry.chemical_compoundImmersionAnimalsEuglena gracilisImmunologic FactorsEnvironmental ChemistrySerum amyloid AbiologyGene Expression ProfilingVaccinationEnteric redmouth diseaseAcute-phase proteinGeneral MedicineHead Kidneybiology.organism_classificationAntibodies BacterialSurvival AnalysisVaccinationstomatognathic diseasesGene Expression RegulationchemistryOncorhynchus mykissBacterial Vaccinesbiology.proteinCytokinesMuramidaseRainbow troutYersinia ruckeriAntibodyLysozymeAcute-Phase ProteinsFish & Shellfish Immunology
researchProduct

Mapping routine measles vaccination in low- and middle-income countries

2021

The safe, highly effective measles vaccine has been recommended globally since 1974, yet in 2017 there were more than 17 million cases of measles and 83,400 deaths in children under 5 years old, and more than 99% of both occurred in low- and middle-income countries (LMICs)1–4. Globally comparable, annual, local estimates of routine first-dose measles-containing vaccine (MCV1) coverage are critical for understanding geographically precise immunity patterns, progress towards the targets of the Global Vaccine Action Plan (GVAP), and high-risk areas amid disruptions to vaccination programmes caused by coronavirus disease 2019 (COVID-19)5–8. Here we generated annual estimates of routine childhoo…

and promotion of well-beingVacunación MasivaInternationalityDisease preventionchildren under 5 years oldGeographic MappingRural Healthmedicine.disease_causeCross-reactivity0302 clinical medicineRA0421Vaccination Refusal030212 general & internal medicineChildimmunity patternsPediatric0303 health sciencesPublic healthMultidisciplinarybiologyVaccinationUncertaintyIMMUNIZATION3142 Public health care science environmental and occupational healthCOVERAGE3. Good healthTIME3.4 VaccinesChild PreschoolInfectious diseasesA990 Medicine and Dentistry not elsewhere classifiedAntibodyEngineering sciences. TechnologyAFRICAGeneral Science & TechnologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Disease prevention ; COVID-19 ; Public health ; Infectious diseases610 Medicine & healthGlobal Vaccine Action Plan (GVAP)Local Burden of Disease Vaccine Coverage CollaboratorsArticleVaccine Related03 medical and health sciencesmeasles vaccineMeasels ; Vaccination ; Low- and middle-income countries ; Local burden of disease ; Public healthClinical ResearchmedicineHumansHealthcare DisparitiesPreschoolPROGRESS030304 developmental biologybusiness.industryMORTALITYDeveloped CountriesPreventionCommentVacunaciónUrban HealthCOVID-19Prevention of disease and conditionsVirologyCoronavirusGood Health and Well BeingCobertura de Vacunaciónbiology.proteinImmunizationbusinessMeasles
researchProduct

Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine

2020

Coxsackievirus B (CVB) enteroviruses are common pathogens that can cause acute and chronic myocarditis, dilated cardiomyopathy, aseptic meningitis, and they are hypothesized to be a causal factor in type 1 diabetes. The licensed enterovirus vaccines and those currently in clinical development are traditional inactivated or live attenuated vaccines. Even though these vaccines work well in the prevention of enterovirus diseases, new vaccine technologies, like virus-like particles (VLPs), can offer important advantages in the manufacturing and epitope engineering. We have previously produced VLPs for CVB3 and CVB1 in insect cells. Here, we describe the production of CVB3-VLPs with enhanced pro…

and promotion of well-beingvirusesPROTECTS MICEPOLIOVIRUSCardiovascularcomplex mixturesvirus-like particle (VLP)virus-like particleVaccine RelatedvaccineIMMUNE-RESPONSECoxsackievirus B (CVB)COXSACKIEVIRUS B3lcsh:QH301-705.5PARTICLE VACCINE11832 Microbiology and virologyPreventionrokotteetvirus diseasesMICROSCOPYPrevention of disease and conditionsenteroviruksetHeart DiseaseInfectious DiseasesGood Health and Well Beinglcsh:Biology (General)3.4 VaccinesCoxsackievirus BENTEROVIRUS 71VIRUSImmunization3111 BiomedicineInfectionRECEPTOR-BINDINGB1Biotechnology
researchProduct

Immunization of rainbow trout, Oncorhynchus mykiss (Walbaum), with a low molecular mass fraction isolated from Flavobacterium psychrophilum.

2008

Flavobacterium psychrophilum, the causative agent of rainbow trout fry syndrome has become a widespread fish pathogen in freshwater aquaculture worldwide. In this study, a low molecular mass fraction (P25-33), with an approximate weight of 25-33 kDa, was identified among F. psychrophilum strains in an immunoblotting analysis with anti-F. psychrophilum sera. The immunogenic efficacy of the isolated and extracted P25-33 was investigated in two intraperitoneal immunization trials with rainbow trout, Oncorhynchus mykiss (Walbaum). The first trial included immunizations using P25-33 with Freund's complete adjuvant (FCA) and the second trial included immunizations using P25-33, formalin-inactivat…

animal structuresanimal diseasesVeterinary (miscellaneous)medicine.medical_treatmentFreund's AdjuvantImmunoblottingFlavobacterium psychrophilumEnzyme-Linked Immunosorbent AssayAquatic ScienceBiologyFlavobacteriumMicrobiologyFish DiseasesImmune systemFlavobacteriaceae InfectionsmedicineAnimalsPathogenMolecular massAntibodies BacterialImmunizationOncorhynchus mykissBacterial Vaccinesbiology.proteinRainbow troutImmunizationAntibodyAdjuvantJournal of fish diseases
researchProduct

Predicting COVID-19 booster vaccine intentions.

2022

Achieving broad immunity through vaccination is a cornerstone strategy for long-term management of COVID-19 infections, particularly the prevention of serious cases and hospitalizations. Evidence that vaccine-induced immunity wanes over time points to the need for COVID-19 booster vaccines, and maximum compliance is required to maintain population-level immunity. Little is known of the correlates of intentions to receive booster vaccines among previously vaccinated individuals. The present study applied an integrated model to examine effects of beliefs from multiple social cognition theories alongside sets of generalized, stable beliefs on individuals' booster vaccine intentions. US residen…

behavior changeand promotion of well-beingCOVID-19 VaccinesIntentionVaccine Relatedintegrated modelsClinical ResearchBehavioral and Social ScienceHumansPsychologyVaccinesPreventionrokotteetsosiaalinen kognitioVaccinationCOVID-19social cognition theoryPrevention of disease and conditionsrokotusGood Health and Well Being3.4 Vaccinesterveyskäyttäytyminenvaccine attitudes and beliefsvaccine hesitancyImmunizationrokotevastaisuus
researchProduct

Yeast Killer Toxin-Like Candidacidal Ab6 Antibodies Elicited through the Manipulation of the Idiotypic Cascade

2014

A mouse anti-anti-anti-idiotypic (Id) IgM monoclonal antibody (mAb K20, Ab4), functionally mimicking a Wyckerhamomyces anomalus (Pichia anomala) killer toxin (KT) characterized by fungicidal activity against yeasts presenting specific cell wall receptors (KTR) mainly constituted by β-1,3-glucan, was produced from animals presenting anti-KT Abs (Ab3) following immunization with a rat IgM anti-Id KT-like mAb (mAb K10, Ab2). MAb K10 was produced by immunization with a KT-neutralizing mAb (mAb KT4, Ab1) bearing the internal image of KTR. MAb K20, likewise mAb K10, proved to be fungicidal in vitro against KT-sensitive Candida albicans cells, an activity neutralized by mAb KT4, and was capable of…

beta-GlucansPhage displayImmunogenPichia anomalaHumoral Immune ResponseAntibody Responselcsh:MedicinePichiaMiceCandida albicansVaccines DNAlcsh:ScienceImmune ResponseMultidisciplinaryVaccinationCandidiasisInfectious Disease ImmunologyKiller Factors YeastAntibodies Anti-IdiotypicVaccines SubunitResearch Articlemedicine.drug_classMolecular Sequence DataImmunologyReceptors Cell SurfaceMycologyBiologyMonoclonal antibodyMicrobiologyMicrobiologyFungal ProteinsAntigenPeptide LibrarymedicineAnimalsAmino Acid SequencePeptide libraryFungal vaccineMolecular Mimicrylcsh:RImmunityBiology and Life Sciencestossina killer mAb K20 Anti-idiotypic peptide mimic candidacidal activityMycotoxinsMolecular biologyRatsHemocyaninsHumoral Immunitybiology.proteinClinical Immunologylcsh:QFungal VaccinesPeptidesKeyhole limpet hemocyaninPLoS ONE
researchProduct

Spontaneous Regression of a Recalcitrant Wart after Bivalent Papillomavirus Vaccination

2017

business.industryCross ProtectionPapillomavirus InfectionsRemission SpontaneousVirologyBivalent (genetics)Vaccination030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisPediatrics Perinatology and Child HealthHumansMedicineFemalePapillomavirus VaccinesWartsHuman papillomavirusChildbusinessPapillomaviridaeThe Journal of Pediatrics
researchProduct

A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis

1996

Background Concern about both safety and efficacy has made the use of whole-cell pertussis vaccines controversial. In some European countries, including Italy, the rate of vaccination against pertussis is low. Methods We conducted a double-blind trial in Italy in which infants were randomly assigned to vaccination at two, four, and six months of age with an acellular pertussis vaccine together with diphtheria and tetanus toxoids (DTP); a DTP vaccine containing whole-cell pertussis (manufactured by Connaught Laboratories); or diphtheria and tetanus toxoids without pertussis (DT). The acellular DTP vaccine was either one containing filamentous hemagglutinin, pertactin, and pertussis toxin ina…

business.industryDiphtheriaFilamentous haemagglutinin adhesinGeneral Medicinemedicine.diseasePertussis toxincomplex mixturesVirologyVaccinationImmunologymedicineDiphtheria-Tetanus VaccinePertactinbusinessDiphtheria-Tetanus-acellular Pertussis VaccinesWhooping coughNew England Journal of Medicine
researchProduct

Vaccination Status and Attitudes towards Vaccines in a Cohort of Patients with Celiac Disease.

2022

(1) Background: The identification of vaccination status and attitudes towards vaccines among celiac disease (CD) patients is of great importance, but it has not yet been investigated. The aim of this study was to investigate coverage against vaccine-preventable diseases (VPDs), attitudes towards vaccinations, and its determinants among CD patients. (2) Methods: An anonymous web-based validated questionnaire was sent to a mailing list of CD adult patients. Patients were asked to self-report their previous vaccinations and attitudes towards vaccinations, which were defined as positive, negative, and partially positive/negative. The influencing factors towards vaccinations were investigated, …

celiac disease coeliac disease hyposplenism vaccine hesitancy vaccinesSettore BIO/13 - Biologia Applicatahyposplenismvaccine hesitancyvaccinesvaccines; vaccine hesitancy; celiac disease; coeliac disease; hyposplenismcoeliac diseaseceliac diseaseVaccines
researchProduct